S-1954 — Biosimilar Red Tape Elimination Act

YourVoice.Now Summary

Average Household ImpactCorporate BenefitsTransparency & Accountability

Every FDA-licensed biosimilar would count as interchangeable automatically, easing pharmacy substitution without a separate FDA finding.

Average Household Impact

Pharmacy substitution — All licensed biosimilars deemed interchangeable with the brand product
Separate interchangeability review — FDA no longer makes a distinct finding before substitution

Corporate Benefits

Interchangeability filing burden — Separate showing no longer required of biosimilar makers
Existing exclusivity protection — Unexpired first-interchangeable periods preserved for their full term

Transparency & Accountability

Guidance prerequisite — FDA guidance is optional and its absence cannot delay an application

The details

Biosimilars are near-copies of expensive biologic drugs, like the ones used for arthritis or cancer. Today a biosimilar needs a second, separate FDA finding to be labeled "interchangeable." That label is what usually lets a pharmacist swap it for the brand without calling the prescriber. This measure ends the separate label. Any biosimilar the FDA licenses would count as interchangeable automatically. The change would take effect 60 days after enactment for drugs already on the market. Newly licensed biosimilars would qualify the day they are approved. One exception applies: if a competitor still holds an unexpired exclusivity period as the first interchangeable version of the same drug, the automatic status waits until that period runs out. Exclusivity periods already running are preserved. The FDA could issue guidance on what biosimilarity data it wants, but is not required to, and its absence could not hold up an application.

Congressional Summary

Congress's official summary of this bill still describes an earlier version of the text, so we have left it out here. You can read it on Congress.gov.

Congress.gov →

Legislative Subjects

Drug safety, medical device, and laboratory regulationGovernment information and archivesLicensing and registrationsPrescription drugs

Details

Congress: 119th
Chamber: Senate
Status: summarized
Action: Introduced in Senate
Action Date: 2025-06-04
Date Added: 2026-08-01
Source: Congress.gov →

Like reading a bill in plain English?

We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.